Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eflornithine + lomustine versus lomustine alone in recurrent anaplastic astrocytoma
2016-000089-45Phase 3Completed
- Sponsor
- Orbus Therapeutics
- Start
- Jun 2016
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in anaplastic astrocytoma (AA) comparing Eflornithine + lomustine with Lomustine alone (2 arms). Primary endpoint: Overall survival. Started Jun 2016; status: completed.
02
Drugs
eflornithinelomustine
03
Conditions
anaplastic astrocytoma (AA)
Beyond the preview
Go deeper on 2016-000089-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000089-45.